ABOS (Acumen Pharmaceuticals) YoY EPS Growth: 31.25% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ABOS Acumen Pharmaceuticals Inc ABOS
34 GF Score
Price $2.24
! 3 Warning Signs
View Full Analysis

What is Acumen Pharmaceuticals YoY EPS Growth?

Acumen Pharmaceuticals ABOS 34 YoY EPS Growth is 31.25% as of Mar. 2026. GuruFocus rates ABOS with a GF Score™ of 34/100. The stock has 3 warning signs investors should review.

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Acumen Pharmaceuticals's YoY EPS Growth for the quarter that ended in Mar. 2026 was 31.25%.

Acumen Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Mar. 2026 was $-0.33.

Acumen Pharmaceuticals YoY EPS Growth Historical Data

* Premium members only.

The historical data trend for Acumen Pharmaceuticals's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Acumen Pharmaceuticals YoY EPS Growth Chart

Acumen Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EPS Growth
Get a 7-Day Free Trial -1,860.94 78.88 -1.89 -58.33 -16.96

Acumen Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -92.00 -100.00 12.00 33.87 31.25
ABOS
34GF Score
Acumen Pharmaceuticals Inc ABOS
YoY EPS Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Acumen Pharmaceuticals YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Acumen Pharmaceuticals's YoY EPS Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EPS Growth (A: Dec. 2025 )
=(Earnings per Share (Diluted) (A: Dec. 2025 )-Earnings per Share (Diluted) (A: Dec. 2024 ))/ | Earnings per Share (Diluted) (A: Dec. 2024 ) |
=(-2--1.71)/ | -1.71 |
=-16.96 %

Acumen Pharmaceuticals's YoY EPS Growth for the quarter that ended in Mar. 2026 is calculated as:

YoY EPS Growth (Q: Mar. 2026 )
=(Earnings per Share (Diluted) (Q: Mar. 2026 )-Earnings per Share (Diluted) (Q: Mar. 2025 )) / | Earnings per Share (Diluted) (Q: Mar. 2025 )) |
=(-0.33--0.48)/ | -0.48 |
=31.25 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EPS Growth →
What does a YoY EPS Growth of 31.25% mean?
Acumen Pharmaceuticals (ABOS) has a YoY EPS Growth of 31.25% as of Mar. 2026. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Acumen Pharmaceuticals and its competitors.
Is Acumen Pharmaceuticals' YoY EPS Growth too high?
Acumen Pharmaceuticals' current YoY EPS Growth is 31.25%. Overall, Acumen Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Acumen Pharmaceuticals' YoY EPS Growth compare to KRRO and CRBU?
Acumen Pharmaceuticals' YoY EPS Growth of 31.25% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EPS Growth for a Biotechnology company?
A good YoY EPS Growth depends on the Biotechnology industry context. However, YoY EPS Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EPS Growth mean?
A high YoY EPS Growth can signal that a stock is expensive relative to its fundamentals. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Acumen Pharmaceuticals and its competitors. Acumen Pharmaceuticals's current YoY EPS Growth is 31.25%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acumen Pharmaceuticals stock overvalued right now?
Acumen Pharmaceuticals (ABOS) has a current YoY EPS Growth of 31.25%. The current YoY EPS Growth is 31.25%. Acumen Pharmaceuticals' overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EPS Growth calculated?
YoY EPS Growth is calculated from a company's financial statements. For Acumen Pharmaceuticals (ABOS), the current YoY EPS Growth is 31.25% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Acumen Pharmaceuticals Business Description

Address 1210-1220 Washington Street, Suite 210, Newton, MA, USA, 02465
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.
34GF Score

Get the complete analysis for ABOS

YoY EPS Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.24
Price